Section Arrow
RLYB.NASDAQ
- Rallybio Corporation
Quotes are at least 15-min delayed:2026/07/17 08:03 EDT
Pre Market
Last
 16.3
+0.34 (+2.13%)
Bid
15.7
Ask
16.5
High 16.99 
Low 16.04 
Volume 66 
Regular Hours (Closed)
Last
 15.96
-0.17 (-1.05%)
Day High 
16.5 
Prev. Close
16.13 
1-M High
16.5 
Volume 
53.32K 
Bid
15.7
Ask
16.5
Day Low
15.73 
Open
16.22 
1-M Low
15.59 
Market Cap 
93.55M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 15.84 
20-SMA 15.88 
50-SMA 15.39 
52-W High 17.5738 
52-W Low 3.2 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.36/-0.97
Enterprise Value
93.64M
Balance Sheet
Book Value Per Share
8.67
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
858.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc0.1477+0.0332+29.00%-- 
Pre Market 0.1243 -0.0234 -15.84%
ATAIAtaiBeckley Inc7.15+1.79+33.40%-- 
Pre Market 7.09 -0.06 -0.84%
KAPAKairos Pharma Ltd.0.3399+0.0219+6.89%-- 
Pre Market 0.286 -0.0539 -15.86%
RXRXRecursion Pharmaceuticals3.02-0.29-8.76%-- 
Pre Market 2.9903 -0.0297 -0.98%
IOVAIovance Biotherapeutics4.66-0.08-1.69%-- 
Pre Market 4.58 -0.08 -1.72%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operationsas a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.